AstraZeneca and Daiichi Sankyo Report Initial Results from the P-Ib Trial (TROPION-Lung04) of Datopotamab deruxtecan + Imfinzi as 1L Advanced Non-Small Cell Lung Cancer
- The P-Ib trial evaluating datopotamab deruxtecan (4 or 6mg/kg) + Imfinzi with/out up to 4 cycles of carboplatin in 230 patients with advanced or metastatic NSCLC without actionable genomic alterations
- The results showed an encouraging response with no new safety signals. In doublet (datopotamab deruxtecan + durvalumab) & triplet therapy (datopotamab deruxtecan + durvalumab & carboplatin), ORR (50.0% & 76.9%); PR (50.0% & 76.9%); SD (42.9% & 15.4%); PD (7.1% & 7.7%) & DCR (92.9% & 92.3%), patients were previously untreated (73.7% & 92.9%), respectively
- The results were presented at the IASLC 2023 World Conference on Lung Cancer. In previously treated & untreated patients, the safety profiles were consistent with other clinical trials & known safety profile of each agent, grade ≥3 TEAEs (42.1% in doublet & 71.4% in triplet)
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.